NVAX Today - Aug 13: Earnings Ahead, Caution Looms

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

NVAX Today - Aug 13: Earnings Ahead, Caution Looms

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly investor buddy. I’ve been in the game for a while, and today we’re chatting about Novavax, or NVAX. It was kinda a flat day for them, barely moving – just a little green, up about 0.19%.

So, what’s the scoop? NVAX had a bit of a rally overnight, probably thanks to some positive vibes from Pfizer. You know how it is in the market; one company’s news can spill over into another. But then, there’s this analyst warning that we might see a 20% crash soon. Yeah, that one stung. So, it’s like a mixed bag right now: some optimism, but a lot of caution hanging in the air.

Now, let’s talk about why things are a bit shaky. So, Novavax is gearing up for their Q4 earnings report, and you know how that can get everyone buzzing. But there’s also chatter about a new share shelf they’re planning, which could dilute shares and freak people out. Plus, Bank of America just cut down on their holdings in NVAX. That’s not exactly a vote of confidence, right? Meanwhile, a bunch of other vaccine-related stocks are seeing some movement too, thanks to a recent outbreak and Trump promising a full report on the hantavirus. It’s all a bit chaotic, honestly.

Oh, and just so you know, the U.K. regulator reaffirmed the safety of childhood vaccinations. That’s good news, but it’s kinda overshadowed by all the other drama.

To wrap it up, NVAX is in this weird spot. There’s potential for growth, but a lot of folks are feeling jittery with warnings from analysts and changes in stock holdings. Just remember, I’m here to share info and keep it light, not to give you financial advice. Keep your head up and happy investing!

まだレビューはありません